Lyssn
AI platform for training and quality improvement in behavioral health and human services.
Website: https://www.lyssn.io/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Lyssn |
| Tagline | AI platform for training and quality improvement in behavioral health and human services |
| Headquarters | Seattle, Washington, United States |
| Founded | 2017 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Healthtech (Behavioral Health, Human Services) |
| Technology Type | AI / Natural Language Processing |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+): David Atkins, Zac Imel, Mike Tanana, Tad Hirsch |
| Funding Label | Seed, $1.39M total disclosed (estimated) |
Links
PUBLIC
- Website: https://www.lyssn.io/
- LinkedIn: https://www.linkedin.com/company/lyssn
- Crunchbase: https://www.crunchbase.com/organization/lyssn
- Careers: https://www.lyssn.io/about-us/careers/
- Knowledge Base: https://knowledge.lyssn.io/knowledge/release-notes
Executive Summary
PUBLIC
Lyssn is a Seattle-based AI company applying natural language processing to the recorded conversations that sit at the center of behavioral health and child welfare work, with the goal of measuring fidelity to evidence-based clinical practice at a scale humans cannot reach manually [Lyssn]. The company was founded in 2017 by a group of academic researchers, including CEO David Atkins, Chief Science Officer Zac Imel, and co-founders Mike Tanana and Tad Hirsch, after roughly a decade of NIH-funded research into machine analysis of psychotherapy sessions [BusinessWire, May 2022] [Crunchbase]. Its differentiation is unusually grounded for the category: the platform is built on what the company describes as 17-plus years of academic work and more than 70 peer-reviewed publications, and it is being deployed inside state agencies rather than only private clinics [Lyssn]. Government adoption is the most concrete commercial signal to date, including the District of Columbia Child and Family Services Agency contract announced in November 2022 and reported deployments in Utah and Wyoming family services departments [ONEcare Population Health Academy, 2022] [Lyssn]. Disclosed capitalization is modest, with public records pointing to roughly $1.39M raised across a 2025 seed round and prior NIH grant funding, which is consistent with the founders' research-grant trajectory rather than a traditional venture build [fundz.net, April 2025] [Crunchbase]. Over the next 12 to 18 months, the watch items are whether Lyssn can convert its government beachhead into multi-state contracts, whether it raises a priced institutional round to fund a Head of Product and HHS sales hires it is currently recruiting, and how it positions against better-funded behavioral health AI peers such as Eleos Health [Workable]. For investors looking at the intersection of clinically validated AI and public-sector behavioral health spend, Lyssn is one of the few names whose science layer is independently citable.
Data Accuracy: GREEN -- Confirmed by Crunchbase, BusinessWire, LinkedIn, and the company's primary sources.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS (with public-sector contracting) |
| Industry / Vertical | Behavioral Health, Child Welfare, Human Services |
| Technology Type | AI / NLP / Speech Analytics |
| Geography | North America (HQ Seattle, WA) |
| Growth Profile | Venture Scale, research-grant origin |
| Founding Team | Four co-founders, PhD-led |
| Funding | ~$1.39M disclosed across seed and grants |
Company Overview
PUBLIC
Lyssn was incorporated as Lyssn.io, Inc. in 2017 and is headquartered in Seattle, Washington [Crunchbase] [LinkedIn]. The founding story is closer to a university spinout than a typical SaaS launch: David Atkins and Zac Imel had spent years at the University of Washington studying how to evaluate counselor behavior using machine learning, supported by funding from the National Institutes of Health, and Lyssn was created to commercialize that body of work into a product that clinical organizations could actually deploy [Lyssn] [BusinessWire, May 2022]. Co-founders Mike Tanana and Tad Hirsch rounded out the group with backgrounds in data science and design respectively; Hirsch is listed in third-party databases as a founder and previously held the Chief Design Officer role [GeekWire] [CB Insights].
The company's earliest milestones are research and grant oriented rather than commercial. Tracxn lists Lyssn as having raised across roughly seven funding events, the majority of which are grants [Tracxn]. The first widely reported commercial milestone is the May 2022 BusinessWire announcement that Lyssn's AI would be used to help assess the quality of prevention services delivered under the federal Family First Prevention Services Act, a piece of legislation that pushed states toward measurable, evidence-based child welfare programming [BusinessWire, May 2022]. That was followed in November 2022 by a contract with the District of Columbia Child and Family Services Agency [ONEcare Population Health Academy, 2022], and subsequently by reported adoption inside the Utah and Wyoming state family services systems [Lyssn].
More recent milestones have been product and capital oriented. Fundz.net recorded a $300,000 seed financing on April 11, 2025, and the company has continued to publish release notes and product updates including new data visualization features for customers [fundz.net, April 2025] [Lyssn]. The company's 2025 impact summary highlights media coverage in the Child Welfare League of America's Children's Voice publication and a podcast interview with co-founder Dr. Michael Tanana about applying AI in child welfare, suggesting the team is leaning into thought leadership in the public-sector behavioral health niche [Lyssn].
Data Accuracy: GREEN -- Confirmed by Crunchbase, BusinessWire, LinkedIn, and Lyssn's own publications.
Product and Technology
MIXED
Lyssn's core product is a SaaS platform that ingests recorded conversations (counseling sessions, crisis line calls, child welfare casework interactions) and uses natural language processing to score those interactions against validated clinical fidelity instruments [PUBLIC] [Lyssn]. The company describes itself on its primary site as "the only AI-based QI and training platform built on gold-standard tools that are trusted around the world," and it positions the offering around two use cases: training clinicians and conducting quality improvement (QI) reviews at scale [PUBLIC] [Lyssn]. The technical premise, supported by 70-plus peer-reviewed publications cited on the company's Science page, is that machine analysis can produce reliable measures of constructs such as therapist empathy and adherence to evidence-based protocols that previously required expensive human coders [PUBLIC] [Lyssn].
The platform appears to combine automated scoring with human-in-the-loop review. The company's security page states that, with customer permission, an in-house clinical team reviews a small sample of sessions to assess empathy and other quality metrics, which suggests a hybrid model rather than purely autonomous scoring [PUBLIC] [Lyssn]. Recent product updates listed in the public knowledge base include batch user creation with CustomerID support and new data visualization features for all customers, indicating ongoing investment in administrator tooling and reporting [PUBLIC] [Lyssn]. Beyond that, the public-facing product roadmap is intentionally thin, and Lyssn does not publicly describe its underlying model architecture or whether it relies on proprietary speech models, fine-tuned open-source models, or third-party foundation model APIs [MIXED] (inferred from absence in public materials).
Deployment context matters in this category, and Lyssn's published customer profile skews toward public-sector and large nonprofit human services agencies rather than private payers or provider groups [PUBLIC] [Lyssn]. The differentiation rests less on the model layer and more on the validated measurement instruments, the labeled clinical dataset accumulated through years of academic research, and the regulatory comfort that comes from a PhD-led clinical team. The Head of Product, Sales Account Executive (HHS), and Contracts Manager roles currently posted on Workable suggest the company is staffing for a more formalized commercial motion focused on health and human services buyers [PUBLIC] [Workable].
Data Accuracy: GREEN -- Confirmed by Lyssn primary sources and corroborated by BusinessWire and Workable job postings.
Market Research and Opportunity
PUBLIC
The market Lyssn sits in matters now because federal and state policy is actively pushing behavioral health and child welfare agencies toward measurable, evidence-based service delivery, and those agencies do not currently have the labor to measure quality at scale.
The most relevant policy tailwind is the federal Family First Prevention Services Act, which restructures how states can use Title IV-E funds and requires that prevention services be evidence-based and rated by an independent clearinghouse; Lyssn explicitly positions its product as a tool to help states demonstrate fidelity under this regime [BusinessWire, May 2022]. That regulatory push is paired with persistent workforce shortages in behavioral health and child welfare, a dynamic Lyssn's own thought leadership has emphasized in its coverage by the Child Welfare League of America's Children's Voice publication, which framed AI as a way for child welfare agencies to manage "complex missions, growing service demands, and labor pressures" [Lyssn]. The combination of a measurement mandate plus a labor shortage is what creates a near-term budget for automated quality review.
No independent third-party TAM figures specific to AI-based quality improvement in behavioral health were captured in the available research. The adjacent and substitute markets, however, are observable. On one side sit traditional human supervision and chart-review services, which are labor-bound and expensive. On the other sit conversational intelligence platforms built for sales and contact centers (Gong, CallMiner and similar), which have proven that NLP scoring of recorded conversations is a viable enterprise category but which lack clinical validation. Lyssn's wedge is the narrow but defensible space where the buyer is a state agency or large behavioral health provider, the conversation is clinical, and the scoring instrument has to be defensible to a regulator or an academic reviewer.
| Market Signal | Detail | Source |
|---|---|---|
| Federal policy driver | Family First Prevention Services Act requires evidence-based prevention services | [BusinessWire, May 2022] |
| Public-sector adoption signal | DC CFSA contract announced November 30, 2022 | [ONEcare Population Health Academy, 2022] |
| Multi-state footprint | Reported deployments in Utah and Wyoming family services | [Lyssn] |
| Scientific backing | 17+ years of academic research, 70+ peer-reviewed publications cited | [Lyssn] |
Analyst takeaway: the market case for Lyssn does not rest on a single TAM number; it rests on a measurable regulatory mandate (Family First) plus a documented labor shortage, and the early customer list suggests state child welfare agencies are willing to be first movers.
Data Accuracy: YELLOW -- Policy and customer drivers confirmed by BusinessWire, ONEcare, and primary sources; no independent TAM source captured.
Competitive Landscape
MIXED
Lyssn is positioned as the clinically validated, public-sector-friendly option in a behavioral health AI category where most of the venture capital has flowed to private-payer and provider-facing competitors.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Lyssn | AI quality improvement and training for behavioral health and HHS, public-sector wedge | Seed, ~$1.39M disclosed | 17+ years of academic research, 70+ peer-reviewed publications, state-agency contracts | [Lyssn] [Crunchbase] [fundz.net, April 2025] |
| Eleos Health | AI documentation and care intelligence for behavioral health providers | Growth-stage, multiple priced rounds reported | Provider-side documentation automation and revenue-cycle adjacency | [PUBLIC] (named competitor in structured facts) |
| OPTT Health | Digital mental health platform with clinician tooling | Earlier-stage | Care delivery workflow rather than measurement layer | [PUBLIC] (named competitor in structured facts) |
| Nuna | Healthcare data and analytics | Later-stage, well-capitalized | Broader healthcare data platform, not behavioral-health specific | [PUBLIC] (named competitor in structured facts) |
The segment map breaks into three groups. The incumbents in clinical quality review are not really software companies at all; they are the human supervisors, internal QI teams, and external accreditors who currently sample a small percentage of sessions by hand. The challengers are venture-backed behavioral health AI companies, of which Eleos Health is the most directly comparable in that it also applies NLP to clinical sessions, though Eleos has historically targeted private behavioral health providers and documentation workflows rather than public-sector fidelity measurement. The adjacent substitutes are general-purpose conversation intelligence platforms whose models are technically capable but whose go-to-market and validation story does not survive a state procurement review.
Where Lyssn has a defensible edge today is in the combination of clinical validation and public-sector trust. The 70-plus peer-reviewed publications are not a marketing claim that competitors can replicate in a quarter, and the existing relationships inside state child welfare systems are slow-cycle assets. That edge is durable as long as state agencies remain the dominant buyer for measurable fidelity. It becomes more perishable if the center of gravity shifts to private-payer reimbursement for behavioral health quality, where Eleos Health's provider relationships and capital base would be the stronger asset.
Lyssn's exposure is on capital and commercial reach. With roughly $1.39M disclosed against a competitor set that has raised meaningfully more, Lyssn cannot match enterprise sales headcount or marketing spend, and the open Sales Account Executive and Head of Product roles suggest the commercial team is still being assembled [Workable]. The most plausible 18-month scenario is a bifurcation: Lyssn wins if the federal Family First measurement regime tightens and three to five additional states standardize on its platform for prevention-services fidelity reporting; it loses ground if a better-funded competitor builds an equally credible clinical-validation story and bundles it with documentation or billing workflows that procurement teams already want.
Data Accuracy: YELLOW -- Competitor names confirmed in structured facts; relative funding and positioning partially inferred from public categorization.
Opportunity
PUBLIC
If Lyssn executes, the prize is becoming the default measurement layer for publicly funded behavioral health and child welfare in the United States, a position that is small in logo count but large in regulatory gravity.
The headline opportunity. The single largest outcome Lyssn could plausibly become is the de facto fidelity-measurement infrastructure that state agencies adopt to comply with federal evidence-based-services mandates. The Family First Prevention Services Act created a structural requirement that prevention services be both evidence-based and demonstrably delivered with fidelity, and the cited DC CFSA contract plus reported Utah and Wyoming deployments show that state agencies are willing to procure Lyssn specifically for this purpose [BusinessWire, May 2022] [ONEcare Population Health Academy, 2022] [Lyssn]. The reason this outcome is reachable rather than aspirational is that there are only fifty state child welfare systems plus a finite set of large county systems, the buying criteria explicitly favor clinically validated tools, and Lyssn's 70-plus peer-reviewed publication base is a credential competitors cannot manufacture quickly [Lyssn].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| State Standard | Lyssn becomes the reference platform cited by additional state child welfare systems for Family First fidelity reporting | A multi-state procurement following the DC, Utah, and Wyoming pattern | Existing public-sector deployments and federal regulatory tailwind [BusinessWire, May 2022] [Lyssn] |
| Adjacent Wedge | Expansion from child welfare into crisis lines and broader behavioral health QI inside the same agency buyers | Cross-sell into existing state customer accounts that already run crisis services | Company materials describe the platform as covering "child welfare, crisis, coaching, wellness, or behavioral health interaction" [Lyssn] |
| Research-Grade Data Moat | Lyssn's labeled clinical dataset becomes the training substrate for behavioral health AI that others license | Publication and partnership activity featured in CWLA Children's Voice and similar venues | 17+ years of accumulated research data and continued academic publishing [Lyssn] |
What compounding looks like. The flywheel here is dataset-driven and trust-driven rather than network-effect-driven in the consumer sense. Each state deployment expands the volume and diversity of clinical conversations the platform has scored, which improves the calibration of fidelity measures, which strengthens the peer-reviewed evidence base, which in turn makes the platform easier to procure in the next state. The human-in-the-loop empathy review described on the company's security page suggests Lyssn is actively curating new labeled data as it scales, not just running inference [Lyssn]. The thought-leadership cadence visible in the 2025 impact summary, including the CWLA feature and the Tanana podcast on AI in child welfare, is the distribution side of the same flywheel: it is how a research-led company gets invited into the next state procurement [Lyssn].
The size of the win. No captured third-party report sizes the AI-based clinical fidelity measurement market, so any valuation framing has to be analogical. The closest comparable in conversation intelligence is the broader sales-side category, where public and late-stage private companies have demonstrated that NLP scoring of recorded interactions can support multi-billion-dollar enterprise values. Translating that to Lyssn's narrower but more regulated wedge: if the State Standard scenario plays out and Lyssn captures a meaningful share of state child welfare and behavioral health QI spend over five years, the comparable outcome is a category-defining vertical SaaS business in public-sector behavioral health, with strategic value to larger health-data acquirers (scenario, not a forecast). The downside framing is that even without that outcome, the existing state-agency footprint and clinical validation make Lyssn a plausible tuck-in for a larger behavioral health platform.
Data Accuracy: YELLOW -- Customer signals and policy drivers confirmed by primary and third-party sources; scenario sizing is analogical and explicitly labelled as such.
Sources
PUBLIC
[Lyssn] Lyssn | Training and Quality Improvement AI Solutions for HHS | https://www.lyssn.io/
[Lyssn] About Us | AI Training and QI Solutions Company | https://www.lyssn.io/about-us/
[Lyssn] Our Solutions | AI-Driven Solutions for Training and QI | https://www.lyssn.io/our-solutions/
[Lyssn] Careers | AI Jobs in Healthcare Technology | https://www.lyssn.io/about-us/careers/
[Lyssn] The Science | Evidence-Based AI Training and QI | https://www.lyssn.io/the-science/
[Lyssn] Customers | https://www.lyssn.io/customers/
[Lyssn] Security | Secure, Evidence-Based AI Solutions | https://www.lyssn.io/resources/security/
[Lyssn] Lyssn's 2025 Impact in Behavioral Health and Human Services | https://www.lyssn.io/resources/insights/lyssns-2025-impact-in-behavioral-health-and-human-services/
[Lyssn] Platform Release Notes | https://knowledge.lyssn.io/knowledge/release-notes
[LinkedIn] Lyssn Company Page | https://www.linkedin.com/company/lyssn
[LinkedIn] Zac Imel, Chief Science Officer, Lyssn | https://www.linkedin.com/in/zac-imel-7482582b6/
[LinkedIn] Christina Soma, PhD, Research Scientist and Clinical Implementation Consultant, Lyssn | https://www.linkedin.com/in/christina-soma-phd-778590152/
[Crunchbase] Lyssn Company Profile and Funding | https://www.crunchbase.com/organization/lyssn
[BusinessWire, May 2022] Lyssn AI to Help Assess the Quality of Prevention Services Offered Under Family First Act | https://www.businesswire.com/news/home/20220509006294/en/Lyssn-AI-to-Help-Assess-the-Quality-of-Prevention-Services-Offered-Under-Family-First-Act
[Tracxn] Lyssn 2025 Company Profile, Team, Funding and Competitors | https://tracxn.com/d/companies/lyssn/__zkOasUEWnXBECI6zyi_612XfVcHqSD7qeGR--94CGwk
[PitchBook] Lyssn 2026 Company Profile: Valuation, Funding and Investors | https://pitchbook.com/profiles/company/454503-34
[fundz.net, April 2025] Lyssn $300,000 seed funding round | https://www.fundz.net/fundings/lyssn-funding-round-7b2a7b
[Workable] Head of Product, Lyssn.io, Inc. | https://apply.workable.com/lyssn/j/B165E90903
[Workable] Sales Account Executive, Health and Human Services, Lyssn.io, Inc. | https://apply.workable.com/lyssn/j/0FED747110
[Workable] Contracts Manager, Lyssn.io, Inc. | https://apply.workable.com/lyssn/j/C0E9F5B572
[CB Insights] Lyssn CEO, Founder, Key Executive Team | https://www.cbinsights.com/company/lyssn/people
[ENMEDIA] Lyssn.io: Behavioral Health with AI | https://www.enmedia.network/insights/lyssn-revolutionizing-behavioral-health-ai/
Articles about Lyssn
- Lyssn Wants to Listen to Every Child Welfare Caseworker's Conversation — The Seattle startup is selling state family-services agencies an NLP tool that scores casework calls against evidence-based practice.